TESARO Inc (TSRO) : Oracle Investment Management Inc scooped up 100,000 additional shares in TESARO Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 640,966 shares of TESARO Inc which is valued at $61,763,484.TESARO Inc makes up approximately 11.29% of Oracle Investment Management Inc’s portfolio.
Other Hedge Funds, Including , A.r.t. Advisors sold out all of its stake in TSRO during the most recent quarter. The investment firm sold 13,611 shares of TSRO which is valued $1,311,556. Citadel Advisors added TSRO to its portfolio by purchasing 164,583 company shares during the most recent quarter which is valued at $15,859,218. TESARO Inc makes up approx 0.04% of Citadel Advisors’s portfolio.Blackrock Investment Management reduced its stake in TSRO by selling 11,471 shares or 9.06% in the most recent quarter. The Hedge Fund company now holds 115,081 shares of TSRO which is valued at $11,089,205. TESARO Inc makes up approx 0.01% of Blackrock Investment Management’s portfolio.First Mercantile Trust Co boosted its stake in TSRO in the latest quarter, The investment management firm added 1,410 additional shares and now holds a total of 3,790 shares of TESARO Inc which is valued at $365,204. TESARO Inc makes up approx 0.04% of First Mercantile Trust Co’s portfolio.Blackrock Fund Advisors boosted its stake in TSRO in the latest quarter, The investment management firm added 105,803 additional shares and now holds a total of 1,399,709 shares of TESARO Inc which is valued at $134,875,959. TESARO Inc makes up approx 0.03% of Blackrock Fund Advisors’s portfolio.
TESARO Inc closed down -0.34 points or -0.40% at $84.35 with 4,63,213 shares getting traded on Thursday. Post opening the session at $85.14, the shares hit an intraday low of $83.26 and an intraday high of $85.5599 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, TESARO Inc reported $-1.28 EPS for the quarter, beating the analyst consensus estimate by $ 0.42 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-1.70. The company had revenue of $36.60 million for the quarter, compared to analysts expectations of $2.48 million. During the same quarter in the previous year, the company posted $-1.51 EPS.
Many Wall Street Analysts have commented on TESARO Inc. Lake Street Resumed TESARO Inc on Sep 6, 2016 to “Buy”, Price Target of the shares are set at $114.BofA/Merrill Initiated TESARO Inc on Aug 30, 2016 to “Neutral”, Price Target of the shares are set at $97.RBC Capital Mkts Initiated TESARO Inc on Aug 12, 2016 to “Outperform”, Price Target of the shares are set at $122.
TESARO Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates rolapitant niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1 or NK-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib formerly known as MK-4827 is an orally active and potent poly (ADP-ribose) polymerase and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio Inc. for the discovery and development of antibodies for several specified immuno-oncology targets.